Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis

Mujica-Mota, R; Varley-Campbell, J; Tikhonova, I; Cooper, C; Griffin, E; Haasova, M; Peters, J; ... Hoyle, M; + view all Mujica-Mota, R; Varley-Campbell, J; Tikhonova, I; Cooper, C; Griffin, E; Haasova, M; Peters, J; Lucherini, S; Talens-Bou, J; Long, L; Sherriff, D; Napier, M; Ramage, J; Hoyle, M; - view fewer (2018) Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis. Health Technology Assessment , 22 (49) 10.3310/hta22490 . Green open access

https://ift.tt/2Rs11Am